Following the release of its FY 2017 results, Kedrion will host a General Investor Call on Friday, 25 May at 09.00 GMT / 10.00 CET.
Dial-in numbers (registration required):
ITALY: +39 02 805 88 11
UK: +44 121 281 8003
FRANCE: +33 170918703
GERMANY: +49 69255114451
SPAIN: +34 917699497
Simone Boaglio – Chief of Central Services
Peer Hansen – Global Chief Financial Officer
DOWNLOAD THE FY 2017 RESULTS PRESENTATION
For further information, please write to [email protected].
Kedrion is a leading biopharmaceutical company that specializes in the development, production and distribution of plasma-derived therapeutic products for use in treating serious diseases, disorders and conditions such as immune system deficiencies and coagulation disorders.
The Company operates through a fully integrated business model from the collection of plasma in its own centers in the United States, Hungary and Germany to fractionation and production in its manufacturing facilities located in Italy, Hungary and the United States.
Headquartered in Castelvecchio Pascoli (Italy), Kedrion has over 2,400 employees and a commercial presence in approximately 100 countries worldwide.
Kedrion places a high value on the welfare of those who benefit from its products, as well as on the people and the communities it serves.
Additional information about Kedrion can be found at kedrion.com